Differential proteins screening: cytokines in renal tissues from patients with IgA nephropathy

doi:10.3877/cma.j.issn.2095-3216.2018.03.001

Abstract

Abstract:

Objective

Screening the differential proteins of cytokines in renal tissues from patients with IgA nephropathy (IgAN) in order to elucidate the pathogenesis of IgAN.

Methods

10 patients, 18 to 60 years old, diagnosed as IgAN according to the renal biopsies in our hospital, were selected. 10 cases of renal cell carcinoma in department of urology of our hospital, aged 18 to 60 years, were chosen. Normal renal tissues 6 cm away from the renal cancer were taken as controls. The L-493 cytokine antibody microarray was used to screen the renal tissues for differentially-expressed proteins which were subsequently analyzed with the gene ontology (GO) method. Then interleukin-33 (IL-33) was used for validation in enzyme linked immune sorbent assay (ELISA).

Results

A total of 25 differentially-expressed proteins were detected. The GO analysis showed that these proteins were related to stress, cell adhesion, protein metabolism, and signal transduction. And the ELISA results showed that the expression of IL-33 in the renal tissues of patients with IgAN was significantly higher than that in the control group.

Conclusions

The differentially-expressed proteins in the renal tissues of IgAN patients may directly or indirectly regulate inflammation, cell proliferation, apoptosis, and fibrosis. IL-33 may be involved in the pathogenesis of IgAN.

Key words: IgA nephropathy, Tissue proteome, Biomarker

Wei Zheng, Yang Lyu, Xiaodong Geng, Quan Hong, Di Wu. Differential proteins screening: cytokines in renal tissues from patients with IgA nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(03): 97-101.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2018.03.001

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2018/V07/I03/97

Figures/Tables 4

References 18

[1]	Xie Y, Chen X. Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China [J]. Am J Nephrol, 2008, 28(1): 1-7.
[2]	Lai KN. Pathogenesis of IgA nephropathy [J]. Nat Rev Nephrol, 2012, 8(5): 275-283.
[3]	Jin KB, Choi HJ, Kim HT, et al. Cytokine array after cyclosporine treatment in rats [J]. Transplant Proc, 2008, 40(8): 2682-2684.
[4]	Liu BC, Zhang L, Lv LL, et al. Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease [J]. Am J Nephrol, 2006, 26(5): 483-490.
[5]	Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines [J]. Immunity, 2005, 23(5): 479-490.
[6]	Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5＋ T cells and promotes allergic-induced airway inflammation independent of IL-4 [J]. J Immunol, 2008, 181(7): 4780-4790.
[7]	Palmer G, Talabot-Ayer D, Lamacchia C, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis [J]. Arthritis Rheum, 2009, 60(3): 738-749.
[8]	Li D, Guabiraba R, Besnard AG, et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice [J]. J Allergy Clin Immunol, 2014, 134(6): 1422-1432.
[9]	Zhang J, Wang Z, Xu Z, et al. The potential role of IL-33 in renal transplant recipients with chronic allograft dysfunction [J]. Ann Transplant, 2016, 21: 611-618.
[10]	Demirtas L, Turkmen K, Kandemir FM, et al. The possible role of interleukin-33 as a new player in the pathogenesis of contrast-induced nephropathy in diabetic rats [J]. Ren Fail, 2016, 38(6): 952-960.
[11]	Yang F, Zhu P, Duan L, et al. IL-33 and kidney disease [J]. Mol Med Rep, 2016, 13(1): 3-8.
[12]	Deffit SN, Blum JS. A central role for HSC70 in regulating antigen trafficking and MHC class II presentation [J]. Mol Immunol, 2015, 68(2Pt A): 85-88.
[13]	Kim SY, Lee HM, Kim KS, et al. Noninvasive biomarker candidates for cadmium-induced nephrotoxicity by 2DE/MALDI-TOF-MS and SILAC/LC-MS proteomic analyses [J]. Toxicol Sci, 2015, 148(1): 167-182.
[14]	Wyatt RJ, Julian BA. Activation of complement in IgA nephropathy [J]. Am J Kidney Dis, 1988, 12(5): 437-442.
[15]	Liu N, Mori N, Iehara N, et al. Soluble fibrin formation in the mesangial area of IgA nephropathy [J]. Clin Exp Nephrol, 2007, 11(1): 71-76.
[16]	Aziz MA, Badary DM, Hussein MR. Renal damage following alloxan-induced diabetes is associated with generation of reactive oxygen species, alterations of p53, TGF-beta1 and extracellular matrix metalloproteinases in rats [J]. Cell Biol Int, 2017, 41(5): 525-533.
[17]	Brany D, Dvorska D, Slavik P, et al. Survivin and gynaecological tumours [J]. Pathol Res Pract, 2017, 213(4): 295-300.
[18]	Musial K, Bargenda A, Zwolinska D. Urine survivin, E-cadherin and matrix metalloproteinases as novel biomarkers in children with chronic kidney disease [J]. Biomarkers, 2015, 20(3): 177-182.

组别	例数	年龄(岁)	身高(cm)	体重(kg)	BMI(kg/m²)	收缩压(mmHg)	舒张压(mmHg)
IgAN组	10	42.90±7.37	169.50±7.56	71.00±15.71	24.51±3.76	124.80±15.53	78.70±6.70
对照组	10	39.40±8.06	164.60±7.98	72.10±10.61	26.59±3.32	128.30±18.46	82.10±15.00
t值	?	1.014	1.410	0.184	1.308	0.459	0.654
P值	?	0.33	0.61	0.49	0.99	0.36	0.04
组别	例数	血糖(mmol/L)	甘油三脂(mmol/L)	总胆固醇(mmol/L)	谷丙转氨酶(U/L)	谷草转氨酶(U/L)
IgAN组	10	4.80±0.55	1.24±0.86	3.98±0.61	20.43±12.50	16.77±4.70
对照组	10	4.93±0.68	1.88±0.78	5.46±1.13	35.43±40.54	29.72±36.83
t值	?	0.471	1.729	3.633	1.118	1.103
P值	?	0.33	0.97	0.04	0.17	0.06
组别	尿素氮(mmol/L)	肌酐(μmol/L)	尿酸(μmol/L)	白蛋白(g/L)	肾小球滤过率[ml/(min·1.73 m²)]
IgAN组	4.70±1.53	68.56±11.0	309.75±104.27	41.24±3.28	105.14±12.48
对照组	4.79±1.22	75.84±13.87	295.51±107.37	37.94±3.86	102.56±17.1
t值	0.149	1.30	0.301	2.060	0.384
P值	0.23	0.89	0.81	0.45	0.42

组别	例数	年龄(岁)	身高(cm)	体重(kg)	BMI(kg/m²)	收缩压(mmHg)	舒张压(mmHg)
IgAN组	10	42.90±7.37	169.50±7.56	71.00±15.71	24.51±3.76	124.80±15.53	78.70±6.70
对照组	10	39.40±8.06	164.60±7.98	72.10±10.61	26.59±3.32	128.30±18.46	82.10±15.00
t值	?	1.014	1.410	0.184	1.308	0.459	0.654
P值	?	0.33	0.61	0.49	0.99	0.36	0.04
组别	例数	血糖(mmol/L)	甘油三脂(mmol/L)	总胆固醇(mmol/L)	谷丙转氨酶(U/L)	谷草转氨酶(U/L)
IgAN组	10	4.80±0.55	1.24±0.86	3.98±0.61	20.43±12.50	16.77±4.70
对照组	10	4.93±0.68	1.88±0.78	5.46±1.13	35.43±40.54	29.72±36.83
t值	?	0.471	1.729	3.633	1.118	1.103
P值	?	0.33	0.97	0.04	0.17	0.06
组别	尿素氮(mmol/L)	肌酐(μmol/L)	尿酸(μmol/L)	白蛋白(g/L)	肾小球滤过率[ml/(min·1.73 m²)]
IgAN组	4.70±1.53	68.56±11.0	309.75±104.27	41.24±3.28	105.14±12.48
对照组	4.79±1.22	75.84±13.87	295.51±107.37	37.94±3.86	102.56±17.1
t值	0.149	1.30	0.301	2.060	0.384
P值	0.23	0.89	0.81	0.45	0.42

Please choose a citation manager

Content to export